Aelis Farma: Availability of the 2023 Universal Registration Document
Published
BORDEAUX, France--(BUSINESS WIRE)--Regulatory News: Aelis Farma (ISIN: FR0014007ZB4 – Ticker: AELIS), a clinical-stage biopharmaceutical company specialized in the development of treatments for brain diseases, announces the publication of its 2023 Universal Registration Document (URD) approved by the French Financial Markets Authority (Autorité des Marchés Financiers (AMF)) on April 24, 2024, under number R.24-004. The Universal Registration Document 2023 includes in particular: The 2023 annual
Full Article